SI
HBIO icon

Stephens Inc’s Harvard Bioscience HBIO Stock Holding History

Stephens Inc’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,587
Closed -$549K – 1375
2021
Q2 		$549K Buy
6,587
+1,421
+28% +$101K 0.01% 840
2021
Q1 		$282K Buy
+5,166
New +$251K ﹤0.01% 1026

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Stephens Inc's HBIO Position: Q3 2021 in Review

Stephens Inc sold out of Harvard Bioscience (HBIO) in Q3 2021, closing a stake of 6,587 shares — an estimated $549K sold.

Stephens Inc first reported a position in HBIO in Q1 2021 and held it in 2 quarters. The position peaked at $549K in Q2 2021. 99 funds tracked by Wall St. Rank hold HBIO as of Q3 2021.

  • Stephens Inc reported no remaining Harvard Bioscience position as of Q3 2021 after selling out during the quarter.
  • Stephens Inc sold 6,587 Harvard Bioscience shares in Q3 2021, an estimated $549K.
  • Stephens Inc first reported a position in Harvard Bioscience in Q1 2021 and held it in 2 quarters.
  • Stephens Inc's Harvard Bioscience position peaked at $549K in Q2 2021.
  • 99 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2021.

Based on Stephens Inc's 13F filing for Q3 2021, filed 27 Oct 2021.